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Treatment of differentiated thyroid cancer is a success of modern medicine with the use of radioiodine (
131I). However, a significant
proportion of thyroid cancers may be non-iodine avid. Thyroid tumours are known to express somatostatin receptors. Octreotide,
an analogue of somatostatin, can be combined with a radioactive isotope, such as
111In-DTPA
0 to visualise tumours with high
concentrations of somatostatin receptors. We assessed 18 patients with histologically proven metastatic or locally recurrent non-
iodine avid thyroid carcinoma to determine the usefulness of
111In-DTPA
0 octreotide scintigraphy compared to conventional
radiology in diagnosing sites of metastasis. The diagnosis of metastatic disease was made using conventional radiology and all had
prospective scintigraphy using
111In-DTPA
0octreotide. Of the 18 patients, 14 had octreotide-positive scans. In eight, the octreotide
scans identified the same sites of metastases as conventional radiology, that is, were concordant. In nine patients, conventional
radiology showed more extensive disease than revealed on the octreotide scans. In one patient with widespread bone metastases,
octreotide gave a more detailed assessment of metastatic disease than conventional radiology. These data indicate that
111In-
DTPA
0octreotide imaging for patients with non-iodine avid carcinoma of the thyroid may be a useful diagnostic and staging tool. One
patient with Hurthle cell carcinoma metastatic to bone and a positive octreotide scan has been treated with
90yttrium-labelled
octreotide.
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Treatment of differentiated thyroid cancer is a success of modern
medicine with the use of radioiodine (
131I) for postoperative
ablation of residual normal thyroid and for eradication of
metastatic disease (Vini and Harmer, 2000). Follicular carcinoma
accounts for approximately 20% of all thyroid cancer and is well
known for its ability to concentrate iodine. However, the Hurthle
cell carcinoma (HCC) variant, which represents approximately 3%
of all differentiated thyroid cancers is rarely, if ever, iodine avid
(Vini et al, 1998). It is frequently bilateral or multifocal within the
thyroid gland and often presents with local invasion (Grossman
and Clark, 1997). Hurthle cell carcinoma is associated with a high
rate of locoregional recurrence and significant mortality. Nodal
metastases and extrathyroidal extension predict a worse outcome
(Stojadinovic et al, 2001). Survival analysis and disease-free
intervals in one series demonstrated increasing tumour aggres-
siveness to be papillary, mixed, follicular and HCC, respectively
(Samaan et al, 1983). Apart from HCC, only two thirds of patients
with differentiated thyroid carcinoma will concentrate iodine in
their metastases and, during the course of the disease, uptake will
disappear in a further significant proportion (Schlumberger et al,
1996). Further surgery and external beam radiotherapy are the
mainstay of management for these patients when disease is
localised. For metastatic disease, local palliative radiotherapy may
also be valuable, but response to chemotherapeutic agents is
usually poor.
Somatostatin is a short-acting regulatory peptide hormone
containing a 14 amino-acid chain that has a predominantly
inhibitory role in hormone release within the gastrointestinal tract
and a neurotransmitter/modulatory role in the central nervous
system. However, receptors for somatostatin, which are G-protein-
coupled receptors, occur in multiple sites throughout the body
such as thyroid C cells, lymphocytes, pancreas and the somato-
troph cells of the anterior pituitary. Five human somatostatin
receptor subtypes (sstrs) have been identified (Bell et al, 1995),
which interact with different G-proteins to mediate effects via
inhibition of adenylate cyclase activity (Rens-Domiano et al, 1992;
Law et al, 1993). When octreotide, a synthetic analogue of
somatostatin with a considerably longer half-life, is combined
with a radioactive isotope such as indium-111 (emits gamma
photons of energies 172 and 245keV and Auger electrons with
tissue penetration 0.02–500mm), peptide receptor imaging can be
performed to visualise tumours with a high concentration of
somatostatin receptors (Wilson et al, 1998). Multiple somatostatin
receptor subtypes are known to be present in medullary thyroid
cancer, but actually the majority of thyroid tumours regularly
express most, if not all, of the somatostatin receptor subtypes
(Forssell-Aronsson et al, 2000). Studies indicate the existence of
two groups of receptors – sstr1/sstr4 with virtually no or very low Received 4 February 2003; accepted 15 April 2003
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laffinity and sstr2/sstr3/sstr5 with intermediate to high affinity for
the somatostatin analogues, such as octreotide and lanreotide
(Bruns et al, 1995). The density of the sstrs will affect radioisotope
imaging and targeted therapy.
In this study, patients known to have non-iodine avid metastatic
thyroid carcinoma were assessed with
111In-DTPA
0octreotide
scintigraphy (DTPA¼diethylenetriaminepentaacetic acid) and
this was compared with conventional radiology. The objectives
were to evaluate
111In-DTPA
0octreotide scintigraphy as a diag-
nostic tool and to consider its potential for therapy.
METHODS AND MATERIALS
In total, 18 patients at the Royal Marsden Hospital with non-iodine
avid metastatic or locally recurrent thyroid carcinoma were
identified from the Thyroid Unit computer database of over 2000
patients. All had histologically confirmed diagnosis of thyroid
cancer, with initial treatment usually comprising total thyroidec-
tomy7selective neck dissection. This was followed by TSH
suppression with thyroxine replacement (with exception of the
patient with medullary thyroid carcinoma (MTC) where thyroxine
replacement was not TSH suppressive). A diagnosis of metastatic
disease was made using conventional radiology: plain X-ray,
ultrasound,
99mTc bone scintigraphy, computerised tomography
(CT) or magnetic resonance imaging (MRI). Metastatic disease
found on conventional radiology was confirmed using serial
measurements of serum thyroglobulin (or calcitonin in the case of
MTC).
Patients underwent diagnostic whole-body scanning with radio-
iodine (
131I) and prospective scintigraphy using
111In-DTPA
0oc-
treotide (OctreoScan
s, Mallinckrodt Medical B.V.). Planar and
SPECT images were obtained 24h after injection of 111MBq
111In-
DTPA
0octreotide. Occasionally, these were repeated at 48h if there
was excessive bowel uptake at 24h. All imaging was reported by
experienced radiologists and nuclear medicine physicians; ab-
normalities had to be beyond reasonable doubt or demonstrate
progression from previous scans before being described as
metastasis. Sites of metastases were correlated with results from
conventional imaging. When the octreotide scan demonstrated
each site of metastasis found with conventional radiology, the
imaging was judged ’concordant’. If either conventional radiology
or the octreotide scan demonstrated more extensive metastatic
disease than the other, then it was designated ‘better’.
RESULTS
In total, 18 patients with histologically proven metastatic thyroid
cancer underwent prospective scintigraphy with
111In-DTPA
0oc-
treotide as shown in Table 1. There were 12 patients with HCC,
four with papillary carcinoma, one with follicular carcinoma and
one with MTC. In all, 11 had previously undergone
131I
scintigraphy, which had been negative. Of the remaining seven
patients, six had HCC and one had MTC–both characteristically
non-iodine avid.
Of 18 patients, 14 (78%) had
111In-DTPA
0octreotide-positive
scans that demonstrated abnormalities indicative of metastases. In
eight (44%), there was an excellent correlation (concordance)
between disease found on conventional radiology and that found
with octreotide imaging (Figure 1). In five patients (28%)
conventional radiology showed that disease was more widespread
than indicated by octreotide imaging although this was positive in
some areas. Four patients (22%) with visible metastatic disease on
conventional radiology had negative octreotide scans. In one
patient (6%) with bone metastases only, octreotide scintigraphy
demonstrated more extensive involvement compared with con-
ventional radiology including
99mTc bone scintigraphy. See Table 1.
DISCUSSION
Our results show that
111In-DTPA
0octreotide imaging may be
useful for both staging and monitoring of disease in patients with
non-iodine avid thyroid carcinoma. Of 18 patients with metastatic
disease, 14 showed positive uptake with
111In-DTPA
0octreotide
and in eight of these patients, it was as good as or better than
conventional imaging. Imaging with octreotide does not provide
an alternative to conventional radiology in the staging of non-
iodine avid thyroid cancer, but may provide additional useful
information, particularly in the case of widespread bone metas-
tases. It is well established that the optimum method of
demonstrating skeletal metastases in differentiated thyroid cancer
is by
131I scintigraphy, rather than
99mTc bone scan, due to their
lytic nature. It is perhaps not surprising that, if these bone
metastases also express somatostatin receptors, octreotide scinti-
graphy may prove superior to
99mTc bone scintigraphy.
Our results compare favourably with other studies that have
assessed octreotide scintigraphy in patients with HCC. Tisell et al
reported a series of 10 patients with HCC, eight of whom had
disease localised to the thyroid and this was shown preoperatively
Table 1 Comparison of conventional radiology and
111In-DTPA
0octreotide scintigraphy in 18 patients with non-iodine avid metastatic thyroid carcinoma
Histology Site of metastases Octreotide Concordance
1 Hurthle Bone, lymph nodes, liver, adrenal gland Negative Conventional radiology better
2 Hurthle Lung, hilar lymph nodes, brain Positive Conventional radiology better
3 Hurthle Lung, cervical lymph nodes Positive Concordant
4 Hurthle Skull base Negative Conventional radiology better
5 Hurthle Residual thyroid disease Positive Concordant
6 Hurthle Lung, mediastinal lymph nodes Positive Conventional radiology better
7 Hurthle Bone Positive Octreotide better
8 Hurthle Recurrent soft tissue neck disease Positive Concordant
9 Hurthle Brain, cervical and mediastinal lymph nodes Positive Conventional radiology better
10 Hurthle Sternum Positive Concordant
11 Hurthle Mediastinal lymph node mass Positive Concordant
12 Hurthle Lung Positive Concordant
13 Papillary Bone, lung Positive Conventional radiology better
14 Papillary Liver, lung, mediastinal and hilar lymph nodes Positive Conventional radiology better
15 Papillary Lung Negative Conventional radiology better
16 Papillary Paratracheal lymphnode mass Positive Concordant
17 Medullary Residual soft tissue neck disease Positive Concordant
18 Follicular Lung Negative Conventional radiology better
LNs¼lymph nodes, CR¼conventional radiology.
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las distinct areas of increased uptake of radionuclide. Two further
patients with metastatic HCC had metastases visualised by
octreotide scintigraphy (Tisell et al, 1999). Valli et al (1999) used
somatostatin receptor imaging in an attempt to detect metastases
in patients with previously treated non-iodine avid thyroid cancer
and an elevated thyroglobulin but was of no benefit over
conventional imaging.
In a study by Gorges et al (1999) eight of nine patients with
metastatic HCC showed
111In-pentetreotide accumulation of
various intensity, while
131I scans were negative except for one
patient. The octreotide scans were compared to FDG-PET scans
and found to be slightly inferior. A major advantage of
scintigraphy using octreotide compared to radioiodine is that
patients do not have to withdraw thyroid hormone. This was
emphasised by Haslinghuis et al (2001) in a series of 25 patients
with differentiated thyroid cancer, who also showed that 75%
patients with lesions that did not concentrate radioiodine did show
uptake of octreotide. Gulec et al (1998) described three patients
with HCC and found all to have positive octreotide scintigraphy.
Different methods of assessing distant metastases in HCC have also
been described, such as lung deposits demonstrated with
131I
labelled anti-carcinoembryonic antigen (CEA) monoclonal anti-
body (Abdel-Nabi et al, 1985) and the incidental finding of HCC in
a neck mass on an FDG-PET during staging for malignant
melanoma (Wiesner et al, 1999).
As useful as peptide receptor scintigraphy is with
111In-
DTPA
0octreotide in diagnosis and monitoring of metastatic non-
iodine avid thyroid cancer, the major interest lies in its potential
for peptide receptor targeted therapy. When the radiopharmaceu-
tical is concentrated within cells, the radioactivity remains in close
proximity to the nuclear DNA, making the radiotoxicity of the
Auger electrons high as it is within their particle range. One patient
from our institution with bone metastases only and a strongly
positive octreotide scan has undergone treatment with the high-
energy beta-emitting
90Y DOTATOC (
90Y DOTA,D-Phe
1,Tyr
3)
octreotide (DOTA¼tetraazacyclododecanetetraacetic acid) and
she has experienced excellent palliation with diminution of pain.
Krenning has suggested that, depending on the homogeneity of
distribution of tumour cells expressing peptide receptors and the
size of tumour, beta-emitting radionuclides, such as
90Y labelled to
DOTA-chelated peptides, may be more effective than
111In for
therapy (Krenning et al, 2000). Waldherr et al have published a
series of 20 patients with progressive thyroid carcinoma who were
refractory to treatment. Although none were reported as having
HCC, all had either a positive
111In-DOTATOC scintiscan or
111In-
DTPA
0octreotide scintiscan. They were treated with 1700–
7400MBqm
 29 0 Y-DOTATOC, which was well tolerated. Stable
disease was reported in 35% and progressive disease in 65%; none
achieved partial or complete response (Waldherr et al, 2001).
Therapy with
111In-DTPA
0octreotide has been reported by
Valkema et al (2002) in a phase I trial. In all, 50 patients with
malignant somatostatin receptor positive tumours were treated,
including six MTC, four papillary and one follicular thyroid
cancers. Of 40 evaluable patients, there was therapeutic benefit
(stabilisation or regression in tumour) seen in 21 (52.5%).
Cumulative doses ranged from 20 to 160GBq and toxicity was
generally only mild bone marrow suppression. However, three out
of six patients who received 4100GBq developed a myelodys-
plastic syndrome or leukaemia and 100GBq was therefore set as
the maximum tolerable dose. No significant renal toxicity was
noted.
Preliminary results of MAURITIUS (Multicenter Analysis of a
Universal Receptor Imaging and Treatment Initiative, a European
Study) have recently been published (Virgolini et al, 2002). Using
cumulative treatment doses up to 7.1GBq,
90Y-DOTA–lanreotide
was used to treat 25 patients with thyroid cancer refractory to
conventional treatment; 56% demonstrated either regression
response (425% reduction in tumour size) or stable disease after
treatment with one to four doses. No severe acute or chronic
haematologic toxicity or change in renal or liver function
parameters was found. The authors recommended careful
consideration of the type of radiotracer for each patient. Whole-
body dosimetry was recommended to predict absorbed doses to
tumours, kidney and bone marrow.
Recently, attempts have been made to induce re-differentiation
in non-iodine avid thyroid tumours using retinoids so as to
increase radioiodine uptake. Simon et al reported a series of 50
patients with inoperable, non-iodine avid advanced thyroid cancer
Figure 1 Comparative images of a patient with an isolated sternal
metastasis secondary to a Hurthle cell thyroid primary tumour. Image (A)i s
cross-sectional CT slice through the deposit. Image (B) is the
111In-
DTPA
0octreotide scan showing intense uptake at the site of the deposit.
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ltreated with 13-cis-retinoic acid. In all, 13 showed a clear increase
in radioiodine uptake and eight, a mild increase. Thyroglobulin
levels were unchanged or decreased in 20 patients (Simon et al,
2002). However, experience at our institution, using retinoic acid
to increase radioiodine uptake in a similar patient group (Short
et al, 2001) has demonstrated no worthwhile benefit. It may still
prove that retinoic acid not only increases radioiodine uptake, but
also the uptake of
111In-DTPA
0octreotide.
CONCLUSIONS
Our study shows that imaging with
111In-DTPA
0octreotide may be
useful both in the staging and monitoring of patients with non-
iodine avid carcinoma of the thyroid. Tumour that has been
identified may be surgically resectable and could result in
prolongation of survival (Vini and Harmer, 2002). For unresect-
able disease, diagnostic scan positive patients may progress to
somatostatin receptor-targeted therapy. It remains to be seen
whether or not receptor-targeted therapy will prove to be a
valuable treatment, but patients with non-iodine avid metastatic
thyroid cancer currently face inexorable tumour progression with
no worthwhile alternative therapy.
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